VSTM Verastem Corp Quarterly Sales Growth

Official company branding of verastem.com (VSTM)

The development of targeted drugs is independent of economic cycles, relying solely on biological risks. The QoQ revenue growth rate demonstrates current volatility, with the value recorded at 114.10. The future of Verastem, Inc. (VSTM) is determined by FDA verdicts on the inhibitor avutometinib and cash runway management. The fate of this biotech ecosystem, which lacks a commercial base, is entirely dependent on the approval of its ovarian cancer therapy.

VSTM (Verastem Oncology) Quarterly Revenue Growth Rate history from 07/04/2022 to 11/20/2026

Analytical breakdowns for Verastem Inc (VSTM)

- stock price and consensus target price:
Summary company analytics:Verastem, Inc. (VSTM)
Flagship merchandise of Verastem Oncology

For the biotech company Verastem, Inc. (VSTM), which is advancing targeted oncology by recruiting leading biochemists, the quarterly sales growth rate reflects the efficiency of commercializing scientific research. This metric compares current revenue with the same period of the previous cycle, allowing investors to promptly identify revenue stagnation or expansion phases to timely adjust portfolios and protect capital from market risks.